Daré Bioscience
June 16, 2025
Company Presentation

Daré Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. We believe that innovation does not have to start from scratch. Our goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women’s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products we identify, in many cases, already have clinical proof of concept or existing safety data for the active ingredient that we leverage. This gives us optionality and flexibility, in many cases, in how we seek to bring solutions to market in ways designed to optimize access for women in a fiscally responsible manner.

Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2015
Lead Product in Development:
Commercial - XACIATO
Launching 2025 - Sildenafil Cream
Phase 3 - Ovaprene hormone-free investigational contraceptive
CEO
Sabrina Martucci Johnson
Development Phase of Lead Product
Multiple Products in Market
Number of Unlicensed Products Looking for Licensing
8
Exchange
NASDAQ
Ticker
DARE
When you expect your next catalyst update?
Sildenafil Cream launch 4Q-2025; Ovaprene interim Phase 3 DSMB mid-2025
What is your next catalyst (value inflection) update?
quarterly updates with SEC filings - next update May 2025
Primary Speaker